NASA scrubs SpaceX launch amid ‘unfavorable' weather
The launch was originally scheduled for 12:09 p.m. ET on Thursday. It has instead been rescheduled for Friday at 11:43 a.m. ET.
'Standing down from today's Falcon 9 launch of Dragon due to cloud cover at the launch site,' a representative for SpaceX explained on X.
Largest digital camera ever built takes first shots of universe
The crew of the mission — Zena Cardman and Mike Fincke of NASA, Kimiya Yui of Japan's Aerospace Exploration Agency, and Oleg Platonov of Russia's Roscosmos space program — are planning to arrive at the International Space Station this week to further study and experiment with methods to maintain the health of astronauts on future missions, including a possible expedition to Mars, according to NASA.
'Other science Crew-11 members will conduct on the space station include studying stem cell production methods to develop advanced cures, new ways to treat bacterial infections, and space agriculture techniques,' NASA says.
On Thursday morning, the crew readied for their mission with a 'long-held spaceflight tradition,' according to NASA: a card game.
'The astronauts are not anything if they're not superstitious, so this is one of those traditions,' a representative for NASA says in a video of this morning's card game.
'The game changes every mission, it's really up to the chief of the office to figure out what that game is going to be. But the goal is the same: You go until the commander wins, and you have shaken off all of the bad luck, if you will.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
BEDFORD, Mass., August 06, 2025--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 11:30 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at About Stoke TherapeuticsStoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit View source version on Contacts Stoke Media & Investor Contacts: Dawn KalmarChief Communications Officerdkalmar@ 781-303-8302 Doug SnowDirector, Communications & Investor RelationsIR@ 508-642-6485
Medscape
17 minutes ago
- Medscape
Dato-DXd Shows Potential in Treating Lung Adenocarcinoma
This transcript has been edited for clarity. I'm Mark Kris, from Memorial Sloan Kettering, continuing a discussion about antibody-drug conjugates, or ADCs, and in this case, datopotamab deruxtecan, or Dato-DXd. This agent combines an anti-TROP2 antibody with a potent topoisomerase I inhibitor. It has had activity in a number of diseases, but the topic today is lung cancer. There has been a phase 3 randomized trial already. It's shown, compared to docetaxel, an improved rate of response by about 10% or so. It showed a small improvement in disease-free survival and about a 1-month improvement in overall survival over docetaxel. I think what this trial shows is that it clearly is an active agent, and I think it's useful to us for patients with adenocarcinoma, giving us an additional line of therapy. It would be a real judgment call when a patient needs a new line of therapy whether to give docetaxel or the Dato-DXd first. The drug is not yet approved for lung cancer but is obviously in the approval process now. The other thing noted in that phase 3 trial was that there was very limited activity. In fact, [there was] less activity than docetaxel in patients with squamous cell cancers. Clearly, that activity is largely limited to the adenocarcinoma patients, and I think that's where, if approved, it will finally be useful. The companion paper in the Journal of Clinical Oncology reports on the use of Dato-DXd in patients whose tumors have oncogenic drivers. They found a higher-than-expected response rate. It was in the twenties in an unselected population, but in the patients with EGFR mutations it was 36%, and in patients with ALK rearrangements in their tumors, it was 44%. I think this may be the place where it will be most useful. In 2025, we still don't have a therapy beyond standard chemotherapy after progression on osimertinib, and this may be a useful drug in that place. Again, it's useful in adenocarcinoma. To summarize, Dato-DXd is a drug in the regulatory approval process that clearly has activity in an unselected population of patients with adenocarcinoma. It's roughly comparable and slightly better than docetaxel. However, it's less effective than docetaxel in a squamous population. In addition, at least in other trials, it has shown some activity and perhaps even more activity in patients with drivers like EGFR or ALK .It may have some usefulness there. I think we're fortunate to have more new agents. We're fortunate to be able to make more choices to match drugs and side effects to specific patient characteristics and specific patient preferences. Once again, our job is better but it's hard. Clearly, the harder we work, the better we're going to make the course of illness for our patients.
Bloomberg
19 minutes ago
- Bloomberg
Virgin Galactic to Delay First Spaceplane Flight to Fall 2026
Virgin Galactic Holdings Inc. is delaying the first commercial flight of its upgraded Delta space vehicle from summer to the fall months of 2026. The Richard Branson-founded company plans to resume private space tourism trips in the autumn after the Delta spacecraft's first operational flight, which will be a research mission and also occur in the fall.
